Dr. Reddy’s Allots Equity Shares Under ESOP on March 26, 2026

An announcement from Dr Reddy’s Laboratories ( (RDY) ) is now available.

On March 26, 2026, Dr. Reddy’s Laboratories allotted 3,675 fully paid equity shares of face value Re.1 each to eligible employees following the exercise of stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007. The issuance, which includes 575 shares at Re.1 and 3,100 shares at Rs.735.80, marginally increases the company’s paid-up equity share capital to 83,46,56,970 shares, with the new shares ranking pari passu with existing stock and underscoring ongoing use of equity-based incentives to align employee interests with shareholders.

The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company headquartered in Hyderabad, Telangana, with equity shares listed on BSE, the National Stock Exchange of India, and American Depositary Receipts listed on the New York Stock Exchange and NSE IFSC. The company operates in the global generics and branded formulations space, supplying medicines across key regulated and emerging markets.

Average Trading Volume: 1,948,731

Technical Sentiment Signal: Hold

Current Market Cap: $11.56B

See more insights into RDY stock on TipRanks’ Stock Analysis page.